
Jupiter Wellness Revenue | JUPW
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Jupiter Wellness
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.12 M | 702 K | 203 K | 121 K | 2.88 M | 1.07 M | 6.46 K | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.88 M | 6.46 K | 1.01 M |
Quarterly Revenue Jupiter Wellness
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 692 K | 793 K | 786 K | 515 K | 1.51 M | 44.9 K | 42.1 K | 182 K | 110 K | 710 K | 171 K | 133 K | 11.9 K | 23.3 K | 34.8 K | -4.79 K | 85.5 K | 3 M | 722 K | 1.54 M | 688 K | 595 K | 48.8 K | 312 K | 178 K | 458 K | 118 K | - | 5.07 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3 M | -4.79 K | 483 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | ||
|
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | ||
|
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M | ||
|
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | ||
|
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B | ||
|
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | ||
|
Solid Biosciences
SLDB
|
8.09 M | $ 6.35 | 1.85 % | $ 556 M | ||
|
TherapeuticsMD
TXMD
|
3.02 M | $ 1.82 | -4.71 % | $ 21.1 M | ||
|
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | ||
|
cbdMD
YCBD
|
19.2 M | $ 0.37 | 1.62 % | $ 1.49 M | ||
|
Aurora Cannabis
ACB
|
175 M | $ 4.41 | -2.43 % | $ 242 M | ||
|
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | ||
|
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | ||
|
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | ||
|
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | ||
|
Tilray
TLRY
|
915 M | $ 2.25 | -4.06 % | $ 252 M | ||
|
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | ||
|
Relmada Therapeutics
RLMD
|
5.13 K | $ 2.86 | -4.98 % | $ 113 M | ||
|
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | ||
|
Canopy Growth Corporation
CGC
|
285 M | $ 0.5 | -5.01 % | $ 149 M | ||
|
China Pharma Holdings
CPHI
|
4.14 M | $ 0.51 | 2.18 % | $ 2.19 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 6.38 | 10.0 % | $ 94.8 M | ||
|
Harrow Health
HROW
|
272 M | $ 32.2 | 9.08 % | $ 1.18 B | ||
|
Pacira BioSciences
PCRX
|
726 M | $ 36.48 | 0.05 % | $ 1.63 B | ||
|
Emergent BioSolutions
EBS
|
743 M | $ 5.5 | -1.96 % | $ 294 M | ||
|
Cronos Group
CRON
|
147 M | $ 3.17 | -0.63 % | $ 1.22 B | ||
|
Evolus
EOLS
|
297 M | $ 7.07 | 5.61 % | $ 456 M | ||
|
Organogenesis Holdings
ORGO
|
564 M | $ 0.85 | 4.57 % | $ 108 M | ||
|
Rockwell Medical
RMTI
|
69.3 M | $ 6.32 | -4.38 % | $ 227 M | ||
|
Bausch Health Companies
BHC
|
10.3 B | $ 8.74 | 3.13 % | $ 3.24 B | ||
|
OrganiGram Holdings
OGI
|
160 M | $ 0.68 | -4.46 % | $ 64.8 M | ||
|
Perrigo Company plc
PRGO
|
4.25 B | $ 16.98 | 7.71 % | $ 2.35 B | ||
|
SCYNEXIS
SCYX
|
20.6 M | $ 2.81 | -1.4 % | $ 140 M | ||
|
Veru
VERU
|
16.9 M | $ 2.3 | 7.48 % | $ 33.7 M | ||
|
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B | ||
|
Viatris
VTRS
|
14.3 B | $ 20.27 | -0.86 % | $ 23.2 B | ||
|
Sundial Growers
SNDL
|
946 M | $ 1.35 | 0.37 % | $ 348 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
19.5 M | $ 0.82 | -1.81 % | $ 1.38 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
119 M | - | - | $ 150 M | ||
|
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | ||
|
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M |